As predicted, the ability of our compounds to compete with SMAC peptide for binding to the BIR3 domains of cIAP1 and cIAP2 correlated closely with ability to sensitize tumor cells to cytotoxicity induced by TNF and LT-α. The gene discussed is BIRC3; the disease is neoplasm.